Shares of Health Care sector company Halozyme Therapeutics moved 1.5% today, and are now trading at a price of $40.05. The mid-cap stock's daily volume was 413,235 compared to its average volume of 869,474. The S&P 500 index returned a -0.0% performance.
Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company is based in San Diego and has 393 full time employees. Its market capitalization is $5,643,749,376.
11 analysts are following Halozyme Therapeutics and have set target prices ranging from $28.0 to $72.0 per share. On average, they have given the company a rating of buy. At today's prices, HALO is trading -21.87% away from its average analyst target price of $51.27 per share.
Over the last year, HALO shares have gone down by -30.6%, which represents a difference of -53.1% when compared to the S&P 500. The stock's 52 week high is $58.65 per share and its 52 week low is $29.85. With average free cash flows of $132.71 Million that have been growing at an average rate of 38.5% over the last 6 years, Halozyme Therapeutics declining stock performance may not be reflective of the quality of its underlying business.
| Date Reported | Cash Flow from Operations ($ k) | Capital expenditures ($ k) | Free Cash Flow ($ k) | YoY Growth (%) |
|---|---|---|---|---|
| 2023 | 368,670 | 15,042 | 353,628 | 50.29 |
| 2022 | 240,110 | 4,810 | 235,300 | -21.04 |
| 2021 | 299,440 | 1,457 | 297,983 | 462.76 |
| 2020 | 55,454 | 2,504 | 52,950 | 159.19 |
| 2019 | -85,423 | 4,040 | -89,463 | -65.17 |
| 2018 | -49,500 | 4,663 | -54,163 |
